AVALYN PHARMA INC (AVLN)
Health Care · Biotechnology · NASDAQ
Avalyn Pharma is a clinical-stage biotechnology company developing targeted, inhaled therapies to treat severe respiratory diseases.
What AVALYN PHARMA INC does
Avalyn Pharma is a biopharmaceutical company focused on the development of targeted, inhaled therapies for respiratory diseases. The company leverages proprietary drug-device technologies to advance a pipeline of inhaled product candidates aimed at addressing unmet medical needs in lung-related conditions.
Themes: respiratory disease, inhaled drug delivery
Fundamentals
- Price$25.72 as of 2026-10-08 close
- Market cap$1.1B as of 2026-08-31 (share count; price 2026-10-08)
- P/En/a earnings data not available
- Debt / equity0.14 as of 2026-09-03
- Beta1.46 as of 2026-09-03
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How AVALYN PHARMA INC looks technically
AVALYN PHARMA INC (AVLN): a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 39, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 32, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 3 trading days ago. Trading volume is running unusually high — about 3.2× its 30-day average, a sign of heightened interest.
Trend
8
| Distance from the 200-day | not enough price history yet — needs 200 trading sessions | n/a |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $33.15 | $33.15 |
| 200-day moving average | not enough price history yet — needs 200 trading sessions | n/a |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 30 calendar days ago — the swings before that are what the structure reading is measured on | 30 sessions |
| Wave structure | its recent swings can be read as a completed five-part upward sequence — the pattern Elliott-wave chartists call an impulse — which on that reading would now be due a pullback rather than more of the same; the labelling fails if price closes above 38.695. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible five-wave upward sequence, complete |
| Since the 50/200 cross | not enough price history yet — needs 200 trading sessions | n/a |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 39, with sellers in control | 39.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 32, neither overbought (above 70) nor oversold (below 30) | 31.9 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($24.14 to $33.18) — its "stochastic" reading is 17 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 17.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 31 sessions |
Range
7
| Since a 20-day breakout | it made a new 20-day low about 3 trading days ago | 3 sessions |
|---|---|---|
| Since a 55-day breakout | it made a new 55-day low about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $40.17 (set on 2026-08-18) | $40.17 |
| Given back of the 52-week move | not available for this company yet | n/a |
| Nearest price level | not enough price history yet — needs 252 trading sessions | n/a |
| All-time low | its lowest closing price on record is $24.14 (set on 2026-10-08) | $24.14 |
| Above the all-time low | it is 6.5% above its all-time low | +6.5% |
Volatility
4
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 88% of the past ~6 months) | 88th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.04 between its high and its low — about 8.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.04 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $23.52 and $36.09 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $23.52 – $29.80 – $36.09 |
| Typical daily range (% of price) | its price moves about 8.0% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 8.0% |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 3.2× its 30-day average, a sign of heightened interest | 3.24× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.7% since the prior reading | -0.7% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a hammer | today, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | today |
|---|---|---|
| Since a bullish engulfing | 6 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 6 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.8% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.8% |
|---|---|---|
| Gap filled | a 4.3% gap up opened on 2026-10-02 has been "filled" 3 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 3 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +1.14% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 32.7 percentage points (the stock lost 31.6% while the market gained 1.0%) | -32.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 15.0 percentage points (the stock lost 11.1% while the market gained 3.8%) | -14.9% |
| vs market, 6 months | not available for this company yet | n/a |
| vs market, 12 months | not available for this company yet | n/a |
Signal agreement
2
| Bullish technical signals | 1 of the 6 technical signals we can compute for it is currently in a bullish state: near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 1 of 6 |
|---|---|---|
| Bearish technical signals | 4 of the 6 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 6 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 21% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 10.4% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -20.9% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 15% below the average price paid since 2026-04-30, so the typical buyer over that stretch is under water. That average is $30.28 — a volume-weighted average of daily closes over 102 sessions, not a true tick-by-tick VWAP. | -15.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 20% below the average price paid since it last reported on 2026-08-12 (its 10-Q), so the typical buyer over that stretch is under water. That average is $32.19 — a volume-weighted average of daily closes over 41 sessions, not a true tick-by-tick VWAP. | -20.1% |
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $38.70.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 4 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 18 trading days, since 2026-09-15.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Unusually heavy trading volume · Broke down to a new 20-day low · Printed a hammer candle after a decline · Most volatile (6%+ typical daily range) · At the bottom of its 14-day range (stochastic below 20) · Under water since its last earnings report (below the anchored VWAP) | Learn: adx · rsi · breakout · volume and relative volume
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.40 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$61.80 range $52.00 – $80.00; median $60.00
Analyst estimates, as of 2026-10-06. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AVLN
- Consensus EPS estimate-$0.79 next reporting period, as of 2026-10-06
- Estimate change, 30 days$0.00 from -$0.79, on 2026-09-01, 35-day window
- Readings revised upward0% of 6 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on third parties to conduct clinical trials and manufacture product candidates.","Significant uncertainty regarding the success of clinical trials and regulatory approval of product candidates.","Requirement for additional financing to support long-term operations and pipeline development."]
What changed in the latest 10-Q
AI-assisted comparison of AVLN's 10-Q filed 2026-08-12 against the prior one filed 2026-06-03.
Management's Discussion & Analysis (MD&A)
- Added:
- Added detailed description of AP01, AP02, and AP03 product candidates including MIST, AURA trials and AP03 Phase 1 timing in the Overview section.
- Added net losses of $28.9 million and $20.2 million for the three months ended June 30, 2026 and 2025, respectively, and net losses of $55.8 million and $37.7 million for the six months ended June 30, 2026 and 2025, respectively.
- Added accumulated deficit of $321.2 million as of June 30, 2026.
- Removed:
- Removed net losses of $26.9 million and $17.5 million for the three months ended March 31, 2026 and 2025, respectively.
- Removed accumulated deficit of $292.2 million as of March 31, 2026.
- Removed statement that cash, cash equivalents, and marketable securities were $123.1 million as of March 31, 2026 and expected to fund operations into 2029.
- Reworded:
- Changed IPO net proceeds from approximately $316.1 million with other estimated offering costs of $4.8 million to approximately $316.6 million with offering costs of $4.2 million.
- Changed report period from quarterly data for three months ended March 31, 2026 and 2025 to three and six months ended June 30, 2026 and 2025.
- Notes:
- Newer filing text appears truncated at the end of the MD&A section, so later parts of the section could not be compared.
- Older filing text also appears truncated at the end of the MD&A section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 180 days · read to 2026-10-044 buys ($25M) · 0 sells — 3 buying insiders
Cluster buying: 3 different insiders reported open-market purchases (SEC code P) of AVLN within a 30-day window between 2026-05-01 and 2026-05-01. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Most recent open-market transaction: 2026-05-01. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AVLN's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
3 institutional 13F filers reported holding AVLN as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 3
- Reported shares held 8,730,719
- Reported value $287,415,269
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about AVLN's institutional holders → See what each manager we track holds →
Short interest (FINRA)
AVLN had 2,093,252 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
AVLN had 4.72% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.56 days to cover at the same settlement.
- Reported short interest (shares) 2,093,252
- Short interest (% of shares outstanding) 4.72%
- Prior settlement (shares) 1,930,246
- Reported change 8.44%
- Days to cover (reported) 9.56
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Frequently asked questions
What does AVALYN PHARMA INC (AVLN) do?
Avalyn Pharma is a biopharmaceutical company focused on the development of targeted, inhaled therapies for respiratory diseases. The company leverages proprietary drug-device technologies to advance a pipeline of inhaled product candidates aimed at addressing unmet medical needs in lung-related conditions.
What sector is AVALYN PHARMA INC (AVLN) in?
AVALYN PHARMA INC (AVLN) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Is AVALYN PHARMA INC (AVLN) overbought or oversold right now?
AVALYN PHARMA INC (AVLN) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 32, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AVLN come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.